The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Lucilla Parnetti

Clinica Neurologica

Ospedale S. Maria della Misericordia

Università degli studi di Perugia




Name/email consistency: high



  • Clinica Neurologica, Ospedale S. Maria della Misericordia, Università degli studi di Perugia, Perugia, Italy. 2010 - 2011
  • Clinica Neurologica, Università di Perugia, Perugia, Italy. 2000 - 2011
  • Section of Neurology, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Perugia General Hospital, Italy. 2006 - 2008
  • Institute of Nervous and Mental Diseases, University of Perugia, Italy., adresse ci-dessus. 1999 - 2000
  • Perugia University, Italy. 1997
  • Section of Gerontology and Geriatrics, Perugia University, Italy. 1997


  1. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. Parnetti, L., Chiasserini, D., Andreasson, U., Ohlson, M., Hüls, C., Zetterberg, H., Minthon, L., Wallin, A.K., Andreasen, N., Talesa, V.N., Blennow, K. Acta Neurol. Scand. (2011) [Pubmed]
  2. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., De Carlo, C., Qureshi, M.M., Ardah, M.T., Varghese, S., Bonanni, L., Borroni, B., Tambasco, N., Eusebi, P., Rossi, A., Onofrj, M., Padovani, A., Calabresi, P., El-Agnaf, O. Mov. Disord. (2011) [Pubmed]
  3. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. Chiasserini, D., Parnetti, L., Andreasson, U., Zetterberg, H., Giannandrea, D., Calabresi, P., Blennow, K. J. Alzheimers Dis. (2010) [Pubmed]
  4. Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Parnetti, L., Balducci, C., Pierguidi, L., De Carlo, C., Peducci, M., D'Amore, C., Padiglioni, C., Mastrocola, S., Persichetti, E., Paciotti, S., Bellomo, G., Tambasco, N., Rossi, A., Beccari, T., Calabresi, P. Neurobiol. Dis. (2009) [Pubmed]
  5. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., Pierguidi, L., Tambasco, N., Rossi, A., Calabresi, P. Biol. Psychiatry (2008) [Pubmed]
  6. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Parnetti, L., Lanari, A., Silvestrelli, G., Saggese, E., Reboldi, P. Mech. Ageing Dev. (2006) [Pubmed]
  7. Stroke prevention and statin treatment. Parnetti, L., Caso, V., Lanari, A., Saggese, E., Sebastianelli, M., Tayebati, S.K., Amenta, F. Clin. Exp. Hypertens. (2006) [Pubmed]
  8. Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience. Parnetti, L., Silvestrelli, G., Lanari, A., Tambasco, N., Capocchi, G., Agnelli, G. Clin. Exp. Hypertens. (2006) [Pubmed]
  9. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Parnetti, L., Caso, V., Santucci, A., Corea, F., Lanari, A., Floridi, A., Conte, C., Bottiglieri, T. Neurol. Sci. (2004) [Pubmed]
  10. Hyperhomocyst(e)inemia: a risk factor for cerebrovascular disease. Parnetti, L., Caso, V., Amici, S., Lanari, A., Gallai, V., Bottiglieri, T. Clin. Exp. Hypertens. (2002) [Pubmed]
  11. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Parnetti, L., Amici, S., Lanari, A., Gallai, V. Mech. Ageing Dev. (2001) [Pubmed]
  12. Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia. Parnetti, L., Reboldi, G.P., Gallai, V. Neurology (2000) [Pubmed]
  13. Therapeutic options in dementia. Parnetti, L. J. Neurol. (2000) [Pubmed]
  14. Atrial fibrillation and stroke. Parnetti, L., Gallai, V. Cerebrovasc. Dis. (2000) [Pubmed]
  15. Pathophysiology of vascular dementia and white matter changes. Parnetti, L. Rev. Neurol. (Paris) (1999) [Pubmed]
  16. Cognitive enhancement therapy for Alzheimer's disease. The way forward. Parnetti, L., Senin, U., Mecocci, P. Drugs (1997) [Pubmed]
  17. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Parnetti, L., Tarducci, R., Presciutti, O., Lowenthal, D.T., Pippi, M., Palumbo, B., Gobbi, G., Pelliccioli, G.P., Senin, U. Mech. Ageing Dev. (1997) [Pubmed]
  18. Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. Parnetti, L., Mari, D., Abate, G., Balestreri, R., Cucinotta, D., Coppola, R., Cherubini, A., Ferrari, P., Senin, U. Thromb. Res. (1997) [Pubmed]
  19. Diagnosing Alzheimer's disease in very elderly patients. Relevance of some functional and psychobehavioral aspects assessed by the Gottfries-Bråne-Steen Rating Scale for Dementia. Study Group on Brain Aging, Italian Society of Gerontology and Geriatrics. Parnetti, L., Brooks, J.O., Pippi, M., Caputo, N., Chionne, F., Senin, U. Gerontology (1997) [Pubmed]
WikiGenes - Universities